S&P 500   3,135.96 (-0.32%)
DOW   27,909.60 (-0.38%)
QQQ   204.07 (-0.45%)
AAPL   266.92 (-1.40%)
MSFT   151.36 (-0.26%)
GOOGL   1,342.99 (+0.27%)
CGC   21.27 (+14.05%)
NVDA   212.17 (+0.00%)
MU   46.45 (-3.09%)
BABA   198.71 (-1.58%)
GE   10.99 (-0.99%)
TSLA   339.53 (+1.08%)
AMD   38.91 (-1.82%)
ACB   2.61 (+7.40%)
GILD   66.93 (-0.22%)
S&P 500   3,135.96 (-0.32%)
DOW   27,909.60 (-0.38%)
QQQ   204.07 (-0.45%)
AAPL   266.92 (-1.40%)
MSFT   151.36 (-0.26%)
GOOGL   1,342.99 (+0.27%)
CGC   21.27 (+14.05%)
NVDA   212.17 (+0.00%)
MU   46.45 (-3.09%)
BABA   198.71 (-1.58%)
GE   10.99 (-0.99%)
TSLA   339.53 (+1.08%)
AMD   38.91 (-1.82%)
ACB   2.61 (+7.40%)
GILD   66.93 (-0.22%)
S&P 500   3,135.96 (-0.32%)
DOW   27,909.60 (-0.38%)
QQQ   204.07 (-0.45%)
AAPL   266.92 (-1.40%)
MSFT   151.36 (-0.26%)
GOOGL   1,342.99 (+0.27%)
CGC   21.27 (+14.05%)
NVDA   212.17 (+0.00%)
MU   46.45 (-3.09%)
BABA   198.71 (-1.58%)
GE   10.99 (-0.99%)
TSLA   339.53 (+1.08%)
AMD   38.91 (-1.82%)
ACB   2.61 (+7.40%)
GILD   66.93 (-0.22%)
S&P 500   3,135.96 (-0.32%)
DOW   27,909.60 (-0.38%)
QQQ   204.07 (-0.45%)
AAPL   266.92 (-1.40%)
MSFT   151.36 (-0.26%)
GOOGL   1,342.99 (+0.27%)
CGC   21.27 (+14.05%)
NVDA   212.17 (+0.00%)
MU   46.45 (-3.09%)
BABA   198.71 (-1.58%)
GE   10.99 (-0.99%)
TSLA   339.53 (+1.08%)
AMD   38.91 (-1.82%)
ACB   2.61 (+7.40%)
GILD   66.93 (-0.22%)
Log in

NASDAQ:KPTI - Karyopharm Therapeutics Stock Price, Forecast & News

$15.89
-0.40 (-2.46 %)
(As of 12/9/2019 04:00 PM ET)
Today's Range
$15.71
Now: $15.89
$17.63
50-Day Range
$10.70
MA: $14.33
$18.04
52-Week Range
$3.92
Now: $15.89
$18.70
Volume1.72 million shs
Average Volume1.14 million shs
Market Capitalization$997.73 million
P/E RatioN/A
Dividend YieldN/A
Beta2.59
Karyopharm Therapeutics Inc (Nasdaq: KPTI) is an oncology-focused pharmaceutical company dedicated to the discovery, development, and commercialization of novel first-in-class drugs directed against nuclear export and related targets for the treatment of cancer and other major diseases. Karyopharm's SINE compounds function by binding with and inhibiting the nuclear export protein XPO1 (or CRM1). Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:KPTI
CUSIPN/A
Phone617-658-0600

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$30.34 million
Book Value$3.02 per share

Profitability

Net Income$-178,410,000.00
Net Margins-909.24%

Miscellaneous

Employees332
Market Cap$997.73 million
Next Earnings Date2/27/2020 (Estimated)
OptionableOptionable

Receive KPTI News and Ratings via Email

Sign-up to receive the latest news and ratings for KPTI and its competitors with MarketBeat's FREE daily newsletter.


Karyopharm Therapeutics (NASDAQ:KPTI) Frequently Asked Questions

What is Karyopharm Therapeutics' stock symbol?

Karyopharm Therapeutics trades on the NASDAQ under the ticker symbol "KPTI."

How were Karyopharm Therapeutics' earnings last quarter?

Karyopharm Therapeutics Inc (NASDAQ:KPTI) released its quarterly earnings data on Monday, November, 4th. The company reported ($0.67) EPS for the quarter, beating the Zacks' consensus estimate of ($0.84) by $0.17. The company earned $13.15 million during the quarter, compared to the consensus estimate of $1.61 million. Karyopharm Therapeutics had a negative net margin of 909.24% and a negative return on equity of 187.25%. View Karyopharm Therapeutics' Earnings History.

When is Karyopharm Therapeutics' next earnings date?

Karyopharm Therapeutics is scheduled to release their next quarterly earnings announcement on Thursday, February 27th 2020. View Earnings Estimates for Karyopharm Therapeutics.

What price target have analysts set for KPTI?

5 brokers have issued 1-year price targets for Karyopharm Therapeutics' shares. Their forecasts range from $5.00 to $36.00. On average, they anticipate Karyopharm Therapeutics' stock price to reach $20.00 in the next year. This suggests a possible upside of 25.7% from the stock's current price. View Analyst Price Targets for Karyopharm Therapeutics.

What is the consensus analysts' recommendation for Karyopharm Therapeutics?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Karyopharm Therapeutics in the last year. There are currently 1 sell rating and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Karyopharm Therapeutics.

Has Karyopharm Therapeutics been receiving favorable news coverage?

Headlines about KPTI stock have trended somewhat negative this week, according to InfoTrie Sentiment Analysis. The research group identifies negative and positive news coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Karyopharm Therapeutics earned a news sentiment score of -1.7 on InfoTrie's scale. They also assigned news headlines about the company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the company's share price in the next few days. View News Stories for Karyopharm Therapeutics.

Are investors shorting Karyopharm Therapeutics?

Karyopharm Therapeutics saw a decrease in short interest in November. As of November 15th, there was short interest totalling 10,690,000 shares, a decrease of 11.4% from the October 31st total of 12,070,000 shares. Based on an average daily volume of 1,600,000 shares, the short-interest ratio is presently 6.7 days. Currently, 19.3% of the shares of the stock are short sold. View Karyopharm Therapeutics' Current Options Chain.

Who are some of Karyopharm Therapeutics' key competitors?

What other stocks do shareholders of Karyopharm Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Karyopharm Therapeutics investors own include Gilead Sciences (GILD), NVIDIA (NVDA), Celgene (CELG), Caladrius Biosciences (CLBS), Exelixis (EXEL), Alibaba Group (BABA), Bristol-Myers Squibb (BMY), GW Pharmaceuticals PLC- (GWPH), Micron Technology (MU) and Intercept Pharmaceuticals (ICPT).

Who are Karyopharm Therapeutics' key executives?

Karyopharm Therapeutics' management team includes the folowing people:
  • Dr. Michael G. Kauffman, Co-Founder, CEO & Director (Age 56)
  • Dr. Sharon Shacham, Co-Founder, Pres, Chief Scientific Officer & Co-Chairman of Scientific Advisory Board (Age 49)
  • Mr. Christopher Brett Primiano, Exec. VP, Chief Bus. Officer, Gen. Counsel & Sec. (Age 38)
  • Dr. Mansoor Raza Mirza, Clinical Consultant, Member of Scientific Advisory Board & Director (Age 58)
  • Mr. Michael P. Mason, Sr. VP, CFO & Treasurer (Age 44)

Who are Karyopharm Therapeutics' major shareholders?

Karyopharm Therapeutics' stock is owned by a number of of retail and institutional investors. Top institutional investors include State Street Corp (5.01%), Emerald Advisers LLC (2.42%), Emerald Mutual Fund Advisers Trust (2.31%), Millennium Management LLC (2.05%), Orbimed Advisors LLC (1.70%) and Creative Planning (0.33%). Company insiders that own Karyopharm Therapeutics stock include Christopher Brett Primiano, Ltd Chione, Mansoor Raza Mirza, Michael Kauffman and Sharon Shacham. View Institutional Ownership Trends for Karyopharm Therapeutics.

Which major investors are selling Karyopharm Therapeutics stock?

KPTI stock was sold by a variety of institutional investors in the last quarter, including Orbimed Advisors LLC, Millennium Management LLC, Private Capital Advisors Inc., First Midwest Bank Trust Division and Barclays PLC. Company insiders that have sold Karyopharm Therapeutics company stock in the last year include Ltd Chione, Michael Kauffman and Sharon Shacham. View Insider Buying and Selling for Karyopharm Therapeutics.

Which major investors are buying Karyopharm Therapeutics stock?

KPTI stock was bought by a variety of institutional investors in the last quarter, including State Street Corp, Creative Planning, Emerald Mutual Fund Advisers Trust, Tibra Equities Europe Ltd, California Public Employees Retirement System, Metropolitan Life Insurance Co NY, Man Group plc and Emerald Advisers LLC. View Insider Buying and Selling for Karyopharm Therapeutics.

How do I buy shares of Karyopharm Therapeutics?

Shares of KPTI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Karyopharm Therapeutics' stock price today?

One share of KPTI stock can currently be purchased for approximately $15.91.

How big of a company is Karyopharm Therapeutics?

Karyopharm Therapeutics has a market capitalization of $998.99 million and generates $30.34 million in revenue each year. The company earns $-178,410,000.00 in net income (profit) each year or ($3.14) on an earnings per share basis. Karyopharm Therapeutics employs 332 workers across the globe.View Additional Information About Karyopharm Therapeutics.

What is Karyopharm Therapeutics' official website?

The official website for Karyopharm Therapeutics is http://www.karyopharm.com/.

How can I contact Karyopharm Therapeutics?

Karyopharm Therapeutics' mailing address is 85 WELLS AVENUE SECOND FLOOR, NEWTON MA, 02459. The company can be reached via phone at 617-658-0600 or via email at [email protected]


MarketBeat Community Rating for Karyopharm Therapeutics (NASDAQ KPTI)

Community Ranking:  3.0 out of 5 (star star star)
Outperform Votes:  433 (Vote Outperform)
Underperform Votes:  283 (Vote Underperform)
Total Votes:  716
MarketBeat's community ratings are surveys of what our community members think about Karyopharm Therapeutics and other stocks. Vote "Outperform" if you believe KPTI will outperform the S&P 500 over the long term. Vote "Underperform" if you believe KPTI will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/9/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel